Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Intralytix

Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes (PDFI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04289948
Recruitment Status : Withdrawn (Funding issues meant that development of the study was halted.)
First Posted : February 28, 2020
Last Update Posted : February 28, 2020
Sponsor:
Collaborators:
Wellcome Trust
BioPhage Theraputics Limited
Nottingham University Hospitals NHS Trust
Information provided by (Responsible Party):
University Hospitals of Derby and Burton NHS Foundation Trust

Tracking Information
First Submitted Date  ICMJE September 3, 2018
First Posted Date  ICMJE February 28, 2020
Last Update Posted Date February 28, 2020
Estimated Study Start Date  ICMJE March 1, 2019
Estimated Primary Completion Date June 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 26, 2020)
  • Work Package 1: To assess the safety of the use of anti-staphylococcal phages therapy on the wound bacterial microbiome of uninfected DFU's. [ Time Frame: 7 months ]
    - Safety : Clinically significant change in safety bloods, vital signs, Full Blood Count (FBC), renal function, C-Reactive protein (CRP), Liver function Tests (LFT)s, Adverse events
  • Work Package 2 [ Time Frame: 16 months ]
    To compare the effect on the microbiome of empirical systemic antibiotic therapy alone (ESAT) versus ESAT plus phage therapy in ulcers complicated by mild or moderate infection as assessed by IDSA criteria
  • Work Package 3 [ Time Frame: 16 months ]
    To compare the use of empirical systemic antibiotic therapy versus phage therapy in ulcers complicated by mild infection on the eradication of the infection as assessed by IDSA criteria.
Original Primary Outcome Measures  ICMJE Same as current
Change History No Changes Posted
Current Secondary Outcome Measures  ICMJE
 (submitted: February 26, 2020)
  • Work Package 1: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 7 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. Incidence of new infection
    2. Number of days of antibiotic usage
    3. Change in surface microbiome
    4. Adverse events
    5. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    6. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    7. Patient well-being using a Visual Analogue Scale, 0-100mm.
    8. Vital signs (Resting pulse and blood pressure (BP))
  • Work Package 1: • Impact on the bacterial microbiome of anti-staphylococcal phage gel and systemically chosen antibiotics. [ Time Frame: 7 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. Incidence of new infection
    2. Number of days of antibiotic usage
    3. Change in surface microbiome
    4. Adverse events
    5. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    6. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    7. Patient well-being using a Visual Analogue Scale, 0-100mm.
    8. Vital signs (Resting pulse and blood pressure (BP))
  • Work Package 2: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 7 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
  • Work Package 2: Clinical benefit and patient well-being associated with adding phage gel to systemically chosen antibiotics compared to placebo in the management of mild or moderate infection. [ Time Frame: 16 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
  • Work Package 2: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel. [ Time Frame: 16 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
  • Work Package 3: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 16 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
  • Work Package 3: Clinical benefit and patient well-being associated with phage gel therapy compared to systemically chosen antibiotics in the management of mild infection. [ Time Frame: 16 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
  • Work Package 3: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel. [ Time Frame: 16 months ]
    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:
    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
Official Title  ICMJE Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
Brief Summary Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT
Detailed Description

Work Package 1

WP1 is a safety cohort pilot study targeting patients with DFU which are non-infected as determined by the IDSA criteria. 20 participants will be recruited from Diabetic Foot Clinic at the Royal Derby Hospital. Phage gel will be applied to the index ulcer after the first and second sets of measures at baseline, weeks 1, 2 and 3. Samples will be taken at baseline and weekly up to 4 weeks by surface swab and deep tissue sample for determination of bacterial colonisation using both conventional and genotypic (molecular) microbiological methods, prior to any IMP application.

Work Package 2

WP2 is a pilot double blind, placebo-controlled, randomised study targeting patients with mild or moderate infection of DFUs and comparing systemic antibiotic therapy plus phage gel against systemic antibiotics therapy plus placebo gel. A total of 50 participants from two centres (foot clinics at Royal Derby Hospital and City Campus, Nottingham University Hospitals NHS Trust) will be recruited. Phage gel or placebo will be applied to the index ulcer after the first and second sets of measures at baseline, weeks 1, 2 and 3. Samples will be taken at baseline and weekly up to 4 weeks by surface swab and deep tissue sample for determination of bacterial colonisation using both conventional and genotypic (molecular) microbiological methods

Work Package 3

WP3 is an observer-blind RCT targeting patients with mild diabetic foot infection by IDSA criteria and comparing phage gel with systemic antibiotics. A total of 50 participants from two centres (foot clinics at Royal Derby Hospital and City Campus, Nottingham University Hospitals NHS Trust) will be recruited. Those with moderately severe infections will be withheld from this work package because of the clinical and ethical issues associated with withholding antibiotics in those with a moderately severe infection.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description:
Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT
Primary Purpose: Treatment
Condition  ICMJE
  • Diabetes
  • Diabetic Foot
  • Diabetic Foot Infection
Intervention  ICMJE Drug: Phage
The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.
Study Arms  ICMJE
  • Experimental: Phage
    Intervention: Drug: Phage
  • Placebo Comparator: Placebo
    Intervention: Drug: Phage
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: February 26, 2020)
0
Original Actual Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE September 1, 2022
Estimated Primary Completion Date June 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Diabetes Mellitus according to WHO criteria
  2. are aged 18 years or over
  3. Additionally, patients must meet one of the following criteria to participate in the described Work Package:

    • Patients are only eligible for WP1 if they also have one or more DFUs (area 25mm2) below the malleoli without infection according to IDSA criteria that have been present for at least 4 weeks
    • Patients are only eligible for WP2 if they also have one or more DFUs (area 25mm2) below the malleoli with mild or moderate infection according to IDSA criteria that have been present for at least 4 weeks
    • Patients are only eligible for WP3 if they also have one or more DFUs (area 25mm2) below the malleoli with mild infection according to IDSA criteria that have been present for at least 4 weeks

Exclusion Criteria:

We will exclude patients who meet ANY of the following criteria:

  1. with mental incapacity to give informed consent,
  2. who have other major co-morbidities, which in the opinion of the investigator would mean that the patient would not be able to complete the study
  3. with significant peripheral arterial disease (PAD): ABPI (ankle brachial pressure index) <0.7,
  4. Who have osteomyelitis defined by agreed clinical criteria
  5. who are receiving treatment with systemic glucocorticoids or other immunosuppressants,
  6. who have received systemic or topical antibiotics in the preceding 14 days,
  7. who are judged to require parenteral administration of antibiotics,
  8. Who have been previously recruited to an earlier part of the project
  9. who are women of childbearing age who are at risk of conception
  10. History of antibiotic hypersensitivity
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United Kingdom
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04289948
Other Study ID Numbers  ICMJE DHRD/2018/080
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party University Hospitals of Derby and Burton NHS Foundation Trust
Study Sponsor  ICMJE University Hospitals of Derby and Burton NHS Foundation Trust
Collaborators  ICMJE
  • Wellcome Trust
  • BioPhage Theraputics Limited
  • Nottingham University Hospitals NHS Trust
Investigators  ICMJE Not Provided
PRS Account University Hospitals of Derby and Burton NHS Foundation Trust
Verification Date February 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP